Ebola outbreak: Vaccine trial put on hold
World's worst Ebola outbreak has killed more than 6,000 people in Africa
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The global vaccines alliance said it was committing up to £191m to buy Ebola vaccines, as one experimental treatment hit a snag in a Swiss clinical trial after some subjects reported joint pains.
Scientists are racing to develop Ebola vaccines but much work remains to be done, as evidenced by a decision to pause the Swiss tests of a vaccine from NewLink and Merck.
The alliance, GAVI, which is funded by governments and the Bill & Melinda Gates Foundation, said it was ready to begin procurement as soon as the World Health Organisation (WHO) recommended a vaccine for use.
The world’s worst Ebola outbreak has killed more than 6,000 people in West Africa, and experts believe millions of doses of vaccine may be needed both to help end the current epidemic and to contain future outbreaks.
Researchers hope safe and effective vaccines will get the green light as soon as next year, although there is still uncertainty over how well they will work. Paying for vaccines is also a challenge because the worst affected countries of Sierra Leone, Liberia and Guinea are some of the world’s poorest.
The money now earmarked by Geneva-based GAVI will help bridge the gap and is expected to be enough to procure up to 12 million courses of vaccine.
Reuters
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments